Global Sexual Dysfunction Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Sexual Dysfunction Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Sexual dysfunctions include sexual disorders of men and women that can interfere with their sexual performance, leading to unsatisfied sexual intercourse. The major drugs used in this market are PDE5 inhibitors, whereas other drugs such as hormone-related and transurethral also have a presence in the market.
Sexual Dysfunction Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Sexual Dysfunction Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Male and Female are the major drivers for the industry.
The sexual dysfunction oral drugs segment accounted for the majority market share during 2017 and will continue to grow during the forecast period. The increasing cases of sexual dysfunctions are driving the need for oral therapies such as 5HT1A receptor agonist. The demand for sexual dysfunction oral drugs such as ED drugs will further increase due to the rising awareness among healthcare professionals.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sexual Dysfunction Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, User and Regions Listed in the Report
Pfizer
GlaxoSmithKline
Merck
Eli Lilly
AbbVie
Bayer
Teva Pharmaceutical Industries
Takeda
Apricus Biosciences
Emotional Brain
Ivix LLX
Leadiant Biosciences
NexMed
S1 Biopharma
Vietstar Biomedical Research
Segment by Type
Oral Therapy
Intracavernosal Therapy
Hormonal Therapy
Transurethral Therapy
Segment by User
Male
Female
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Sexual Dysfunction Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Sexual Dysfunction Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Sexual Dysfunction Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Sexual Dysfunction Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product User, Volume and Revenue analysis of Each User in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Sexual Dysfunction Drugs introduction, etc. Sexual Dysfunction Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Sexual Dysfunction Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Sexual Dysfunction Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Sexual Dysfunction Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Male and Female are the major drivers for the industry.
The sexual dysfunction oral drugs segment accounted for the majority market share during 2017 and will continue to grow during the forecast period. The increasing cases of sexual dysfunctions are driving the need for oral therapies such as 5HT1A receptor agonist. The demand for sexual dysfunction oral drugs such as ED drugs will further increase due to the rising awareness among healthcare professionals.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sexual Dysfunction Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, User and Regions Listed in the Report
By Company
Pfizer
GlaxoSmithKline
Merck
Eli Lilly
AbbVie
Bayer
Teva Pharmaceutical Industries
Takeda
Apricus Biosciences
Emotional Brain
Ivix LLX
Leadiant Biosciences
NexMed
S1 Biopharma
Vietstar Biomedical Research
Segment by Type
Oral Therapy
Intracavernosal Therapy
Hormonal Therapy
Transurethral Therapy
Segment by User
Male
Female
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Sexual Dysfunction Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Sexual Dysfunction Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Sexual Dysfunction Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Sexual Dysfunction Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product User, Volume and Revenue analysis of Each User in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Sexual Dysfunction Drugs introduction, etc. Sexual Dysfunction Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Sexual Dysfunction Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.